Anemia
Conference Coverage
Sevuparin failed for acute VOC in sickle cell, but may have preventive potential
The novel nonanticoagulant heparinoid drug sevuparin may have value in the setting of prodromal vaso-occlusive crisis in patients with SCD.
Commentary
The evolving landscape of complement inhibition therapy
The surge of new complement inhibitors could revolutionize our strategy for treatment of autoimmune-mediated diseases.
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
ORLANDO – ASH has released the first of five new sets of sickle cell disease guidelines, with the first focusing on screening and management of...
Conference Coverage
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
ORLANDO – A novel antibody targeted to the complement pathway increased hemoglobin and improved quality of life in patients with cold agglutinin...
Conference Coverage
Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
ORLANDO – The list, which was released by ASH and the American Society of Pediatric Hematology/Oncology, includes five unnecessary tests or...
Conference Coverage
Oral arginine emerges as potential adjuvant for vaso-occlusive crisis management
ORLANDO – Researchers called for a phase 3, multicenter clinical trial to further evaluate the treatment.
Conference Coverage
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.
Conference Coverage
Fragmentation of sickle cell disease care starts in young adulthood
ORLANDO – Imagine what that would be like to have a chronic, debilitating illness and to have to go to multiple different hospitals, during this...
Opinion
The clinical impact of new approvals in sickle cell, MCL
Dr. Alan P. Lyss puts some recent FDA approval of crizanlizumab and zanubrutinib into perspective for clinicians.
News from the FDA/CDC
FDA approves Oxbryta for sickle cell disease treatment
The drug, which is approved for adults and children aged 12 years and older, improved hemoglobin in the HOPE trial.